News

curATalk 02.02.2022

It is our pleasure to announce the upcoming curATime seminar series “curATalk” with Sara Vieira-Silva, PhD and her seminar on  Human gut microbiota variation in health and disease  on February 2nd,  5 pm. Click here for dial-in information.    curATime – Cluster for Atherothrombosis and Individualized Medicine – is one of a total of 15
Read More

Top 20 Translational Biotech Researchers 2020

Ugur Sahin/TRON is the world´s second most successful translational researcher of 2020! The top translational biotech researchers are determined by examining the patents (European and US) that were granted. Ugur Sahin/TRON was granted an impressive amount of 31 patents in 2020. The list highlights recognized leaders in various fields. https://www.nature.com/articles/s41587-021-01107-y.pdf
Read More

Collaborative Research Center 1292 funded for 4 more years

Exciting news! The German Research Foundation (DFG) will fund the Collaboration Research Center 1292 for 4 more years to target inefficient immunity in tumors and chronic infections, to which TRON contributes two projects (TP17 an Q01).   Further information about CRC1292 can be found online: https://crc1292.uni-mainz.de/ Picture Credits: D. Nothmann/Universitätsmedizin Mainz
Read More

Innovation by networking – curATime

TRON has entered the conception phase for the “Cluster for Atherothrombosis and Individualized Medicine – curATime” with its partners from Mainz University Medical Center and the German Research Center for Artificial Intelligence (DFKI). The common goal is to develop tailored, innovative treatment methods, diagnostics and prevention concepts for cardiovascular diseases. curATime aims at networking across
Read More

mRNA-encoding Cytokines Promote Antitumor Immunity and Tumor Eradication

In a recently published preclinical study, scientists from TRON, BioNtech (Germany) and Sanofi (US) share the results of intratumoral administration of mRNAs encoding four cytokines. Cytokines are strong modulators of the immune system and can directly induce tumor cell death, reduce blood vessels in tumors and thus limit supplies of the tumor, or lead to
Read More

TRON uses GSI/FAIR experiment period for cancer research: combination of heavy ion therapy and mRNA vaccine

June 24, 2021 – TRON uses GSI/FAIR experiment period for cancer research: combination of heavy ion therapy and mRNA vaccine It is a strong alliance for research in the fight against cancer, opening the way for exciting new developments. On one hand, the GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt with its worldwide unique accelerator facilities
Read More

curATime – Cluster for Atherothrombosis and Individualized Medicine among the finalists of the BMBF’s “Clusters4Future” initiative

We are very proud to have been selected for the concept phase of the “Clusters4Future” initiative of the Federal Ministry of Education and Research (BMBF). Among this year’s 15 finalists is the cluster concept “curATime – Cluster for Atherothrombosis and Individualized Medicine”, which was developed in collaboration between TRON gGmbH, the Center for Thrombosis and
Read More

Bundesverdienstkreuz for Ugur Sahin and Özlem Türeci

Unsere herzlichen Glückwünsche: TRON-Gründer Ugur Sahin und Özlem Türeci erhalten das Bundesverdienstkreuz für die kurzfristige Entwicklung und Zulassung eines Impfstoffes gegen Covid-19 mit ihrem Unternehmen BioNTech, wie das Bundespräsidialamt mitteilte. Türeci und Sahin hätten durch ihren “unermüdlichen Einsatz” einen “entscheidenden Beitrag zur Eindämmung der Corona-Pandemie geleistet”. Die Verleihung des höchsten deutschen Verdienstordens an das Unternehmerpaar
Read More

Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA

In this recent study published in European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI), researchers from TRON, JGU Medical Center and BioNTech employed an in vitro transcribed mRNA encoding for sodium iodide symporter (NIS) to efficiently visualize and quantify the biodistribution of NIS RNA-lipoplex nanoparticles targeted to spleen or lung. Tissues expressing the RNA-encoded
Read More

Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates

Within the last year, a few infections with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) quickly turned into the global COVID-19 pandemic infecting and threatening death for millions of people all over the globe. The viral spike protein is responsible for viral binding and entry to host cells and thus mediates infection. Hence, the protein
Read More

TRON researchers contribute to newest BioNTech/Pfizer publication in Nature

Congratulations! TRON researcher Fulvia Vascotto was part of the team around Annette B. Vogel and Ugur Sahin, publishing pre-clinical results in Nature. The study supported the rapid development of BioNTech/Pfizer´s vaccine COMIRNATY (BNT162b2), the now globally deployed mRNA based vaccine against Covid-19. The recently published paper displays immune response data of two vaccine candidates (BNT162b1
Read More

Academy Prize of the State of Rhineland-Palatinate for Ugur Sahin and Özlem Türeci

Dr. Özlem Türeci and Prof. Dr. Ugur Sahin have been awarded the Academy Prize of the State of Rhineland-Palatinate for innovative and forward-looking research for their extraordinary achievements leading to the development of a vaccine against the Corona virus. On behalf of all TRON employees, we warmly congratulate Dr. Özlem Türeci and Professor Ugur Sahin,
Read More

Novel RNA-based therapy for treatment of autoimmune diseases

Loss of immunological self-tolerance followed by attack of self-reactive T cells to target organs plays a major role in the formation of autoimmune diseases such as multiple sclerosis (MS). In a very recent study published in Science, our researchers (in collaboration with Johannes Gutenberg University Medical Center and BioNTech) employed a non-inflammatory RNA vaccine that
Read More

Multi-omics characterization of the 4T1 murine mammary gland tumor model

The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome
Read More

A liposomal RNA vaccine augments the antitumor activity of local radiotherapy in mice

TRON is delighted to announce the publication of a scientific article in OncoImmunology.
Read More

TRON wears white for A Future #Immune2Cancer

TRON is proud to join the Cancer Research Institute this June 12 in bringing global awareness about the life-saving potential of cancer immunotherapy. By wearing white together, we are driving the future of immune-based science and medicine for cancer treatments, and ultimately, cures.  Learn more about TRON’s mission and work at www.tron-mainz.de.
Read More

PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation

TRON is delighted to announce a scientific article published in Oncotarget.
Read More

TRON’s activities against the Coronavirus pandemic

As an innovative immunological research institute, TRON was asked by a renowned industrial partner to support the development of a vaccine against the currently pandemic coronavirus with preclinical studies.
Read More

Dr. Luisa Bresadola awarded BMS Young Scientist prize

We are delighted to announce that TRON scientist Dr. Luisa Bresadola has won the Bristol-Myers-Squibb Young Scientist award in the field of immune-oncology! Luisa’s work comprises analysis of head and neck squamous cell carcinoma next-generation sequencing data, generated by TRON in collaboration with the University of Birmingham, to determine tumor evoluation in this cancer entity.
Read More

Miteinander gut leben – Rheinland-Pfalz gegen Hass und Hetze

TRON unterstützt das Anliegen der Landesregierung und tritt gemeinsam mit der Landesregierung für unsere Grundwerte ein. Nur gemeinsam können wir zeigen, dass die Mehrheit für Respekt und gegen Hass steht. „Rheinland-Pfalz ist ein lebenswertes und weltoffenes Land. Das wollen wir auch in Zukunft sein. Deshalb finden wir uns nicht damit ab, dass der Umgang auf
Read More

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.

Although chimeric antigen receptor (CAR)-modified T cells (CAR T-cells) have been shown to be effective against hematological malignancies, evidence of their potential against immune-suppressive solid tumors is missing. Key challenges for this include the selection of tumor-specific targets and the persistence of CAR-T cells upon adoptive transfer.  In this study, teams from Biontech and TRON
Read More

Top 20 Translational Researchers (2018)

Mainz, December 9, 2019 – TRON founders Ugur Sahin and Özlem Türeci have been named among the Top 20 Translational Researchers (2018) for the 2nd time by Nature Biotechnology.    Nature Biotechnology’s ranking is based on the number of total patents (US and European) awarded, the researcher’s top-cited patent over the past 5 years and
Read More

BioNTech IPO

TRON congratulates its cooperation Partner BioNTech SE on its successful IPO!
Read More

Healthcare Hackathon Berlin

After the Healthcare Hackathon at the University Medical Center Mainz, the next round started on September 2nd and 3rd in Berlin. A total of 24 interdisciplinary teams took part in this relaxed competition to develop technology-based solutions for medical applications and care within the scope of their projects. TRON was also represented by Jonas Ibn-Salem
Read More

Author’s Comment: ArtiFuse – Computational validation of fusion gene detection tools without relying on simulated reads

TRON is thrilled to announce an article published in Bioinformatics.
Read More

Author’s Comment: HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

TRON is delighted to announce an article published in Oncoimmunology.  TRON co-author Nadja Salomon shares this Author’s Comment. HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of
Read More

Healthcare Hackathon Mainz

At the Healthcare Hackathon at the University Medical Center Mainz, experts from the field of healthcare met with startups, programmers, and industry partners. In interdisciplinary mixed teams, technology-based solutions were developed for practical challenges in hospitals and care. For TRON, Jonas Ibn-Salem participated in the hackathon and worked with experts from IBM, Garmin, BioNTech and
Read More

CIMT 2019 Poster Award

At the annual meeting of the Association for Cancer Immunotherapy (CIMT) in 2019, six scientists received the CIMT Poster Award. Thomas Rösler, a scientist from TRON, won the prize in the category ‘Therapeutic Vaccination’ for his work ‘Modelling immunogenicity with omics data integration’ (Abstract 37). He presented his algorithm TOPAZ, which defines candidates for cancer
Read More

CIMT 2019 Annual Meeting

The Association for Cancer Immunotherapy CIMT’s Annual Meeting brings the world’s top cancer biology and immunotherapy researchers together in the heart of Europe.  The 2019 Annual Meeting will take place May 21-23 at the Rheingoldhalle Congress Center in Mainz.
Read More

CiiM Lecture Series: Individualized Cancer Immunotherapy

Hannover, May 8, 2019 – The Center for Individualised Infection Medicine CiiM lecture series is held at Hannover Medical School. Ugur Sahin will be speaking about Individualized Cancer Immunotherapy on Wednesday, May 8th at 17:00, in Building J01, Lecture Hall N.  CiiM is a joint institution of the Helmholtz Center for Infection Research (HZI) and
Read More